A biotech early stage investment firm headquartered in Asia invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.
The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.
The firm does not have any specific requirements for companies and their management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Asia-Based Evergreen Fund Backed by a Family Office Invests in Novel Therapeutics, Medical Devices, and Healthcare Services
24 MarHot Investor Mandate: Investment Firm in Western Europe Invests Up to €8M in Therapeutics, Devices, and Digital Health Companies With a Focus on Pre-Clinical Opportunities
24 MarA firm based in Western Europe invests in early stage companies in the life sciences and Information Technology Sectors. The firm also invests in public companies through Convertible Bonds and secondary alternative markets. The firm also offers Venture Debt financing for private companies. Within Life Sciences, the firm invests in rounds of EUR 2-8 Million Seed and Series A rounds. The firm invests in Europe and North America.
In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. Outside of Therapeutics, the firm invests in companies that are revenue positive. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. The firm’s areas of interest include oncology, CNS, dermatology, and ophthalmology (particularly front of eye diseases). The firm has invested in rare diseases but it is not the firm’s sole focus.
In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 8 million to reach a human Proof of Efficacy. In the country they are headquartered in, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. In North America, the firm seeks to co-invest in rounds led by top-tier Venture Capital.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: China-Based Public Biopharma Company Seeks Licensing Opportunities in Oncology, Ophthalmology, and Nephrology, Most Interested in US/EU Companies
24 MarA public biopharmaceutical company with over 20 years operation in China’s pharmaceutical industry is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm is interested in in-licensing clinical stage assets for development, while collaborative R&D can also be considered. Typical equity investments range from $2-3M per deal. The firm has partnered with companies in Japan, the US and Europe. The firm is currently looking for new opportunities globally with a focus on US and EU.
Currently, the firm is seeking therapeutics in oncology, ophthalmology, and nephrology. The firm is most interested in new formulation and is open to small molecule, biologics, biosimilars, and repurposed drugs. The firm currently focuses on assets in phase 2 clinical trials, while it can consider assets from pre-clinical to on-market stages.
The firm is seeking innovative assets that address large unmet medical need. The firm generally seeks development and/or commercialization rights in China and Southeast Asia.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Seeking Capital or Licensing Deal? Here’s Why Digital RESI March is Important
17 MarBy Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series; Caitlin Dolegowski, Marketing Specialist, LSN
Finding the right capital or channel partner is a numbers game, which means that you need to get in front of potential partners regularly. This is why the Redefining Early Stage Investments (RESI) conference takes place five times each year. You never know when a connection will surface that leads to a partnership, so you must be in the game to make it happen.
RESI is different from other partnering conferences in that it does real-time dynamic matching. The team at Life Science Nation (LSN) pre-loads investor profiles from mandates collected and stored in the LSN Investor Database. That is a big deal because (at most partnering events) investors typically have very light or even empty profiles. Because LSN has all the investors and licensing partners’ updated profiles in our database, this makes a huge difference in the quality of RESI meetings.
LSN can match based on fit, which in turn means great meetings can happen as both parties are looking for each other. Instead of booking a meeting and realizing there is no fit (which is common at other partnering conferences), RESI is unique because:
- There is the option to filter partners by capital investment and licensing mandates and match on stage of development and product.
- Most investor and licensing partner profiles are uploaded from our curated partnering database, so the user does not need to update their profile, unless they choose to, which has been a game-changer.
- Scientist-entrepreneurs and fundraising CEOs can opt to upgrade to a premier profile as part of RESI Premier Partnering to access deeper detailed investor mandates, which also include valuable contact information.
Another facet of Digital RESI March is the variety of panels focused on educating the entrepreneur on key components to partnering in the life science and health care early-stage arena. Hear straight from relevant investors and industry experts. These panels are created with the same intent and spirit of our partnering platform – To bring quality content with the early-stage life science entrepreneur in mind. Hear best practices, lessons learned, and valuable insight from our panelists. These panels are available to attendees live or their recordings are available on the meeting platform. Check out the panelists presenting at Digital RESI March below.
Tuesday, March 22, 11 AM EDT
Early-Stage Therapeutics
Bringing the Newest Therapies to the Clinic
 |
 |
 |
| Yaniv Sneor Founder Mid Atlantic Bio Angels (Moderator) |
Cynthia Cai, PhD, MBA Venture Partner Viva BioInnovator |
Catello Somma, MBA Associate ;TVM Capital Life Science |
 |
 |
|
| Scott Weiner Partner, Amzak Health |
Sa’ar Yaniv Director, Business Development, Fortress Biotech |
Tuesday, March 22, 2 PM EDT
Digital Health & Wellness
Silver-Tech Focusing on Preventative Care
 |
 |
 |
| Brenda Hogan, MBA Senior Investment Manager Ontario Capital Growth Corporation (OCGC) (Moderator) |
Moshe Bellows, JD General Partner Maccabee Ventures |
Seemant Jauhari Managing Partner HealthXCapital |
Tuesday, March 22, 3 PM EDT
Seed Funds
Investing in the Earliest Stage Companies
 |
 |
 |
| Andy Merken Partner & Co-Chair, Life Sciences Burns & Levinson (Moderator) |
Dipty Desai, PhD Co-Chair, TiE Global Health TiE Angels |
Matt Martin, PhD, MBA Venture Partner Pathway Bioventures |
 |
||
| Gita Reinitz Principal (NFX Bio) NFX |
Tuesday, March 22, 4 PM EDT
Tales from the Road: AI Innovators on their Fundraising Journey
 |
 |
 |
| Chelsea Sumner, PharmD NALA Healthcare AI Startups Lead NVIDIA (Moderator) |
Davide Vigano Co-Founder & CEO Sensoria |
Ramji Srinivasan Co-Founder & CEO Teiko.bio |
 |
 |
|
| Himanshu Misra, PhD CEO Enliten AI |
Leila Pirhaji, PhD Founder & CEO ReviveMed |
Wednesday, March 23, 10AM EDT
Mental & Behavioral Health Panel
Investing in Technologies that Help Manage Well-Being
 |
 |
 |
| Lana Ghanem, MBA Managing Director Hikma Ventures |
Raj Pallapothu Managing Director Bio 9 Ventures |
Mayank Taneja, MBA Director, Venture Investments OSF Healthcare Ventures |
 |
||
| Charlie Hartwell Operating Partner Bridge Builders Collaborative |
Wednesday, March 23, 11 AM EDT
Age-Tech Devices
Seniors Embrace Innovative Medtech for Better Quality of Life
 |
 |
 |
| Lise Pape Trustee Future Care Capital |
Rick Robinson Vice President, Startup Engagement AARP Innovation Labs |
Clarence Tan, PhD, MBA Co-Founder ABBY by GOGOTECH |
Wednesday, March 23, 2 PM EDT
Medtech Strategics
Large Corporations Seeking External Innovation in MedTech
 |
 |
 |
| David Uffer Senior Partner Alira Health Ventures (Moderator) |
Lana Caron, MBA Innovation Lead Philips Health Technology Ventures |
Juan Cueva, PhD, MBA Director, New Ventures & Early Innovation Partnering Johnson & Johnson Innovation |
 |
||
| Tali Hirsch Director, Venture Investments Fresenius Medical Care Ventures |
Wednesday, March 23, 3 PM EDT
AI Drug Discovery and Development
How AI is Accelerating Therapeutic Advancement
 |
 |
 |
| Rafael Rosengarten, PhD Co-Founder, Board Director & Executive Committee Member The Alliance for Artificial Intelligence in Healthcare (Moderator) |
Galym Imanbayev, MD, MBA Partner Lightspeed Venture Partners |
Linda Li Managing Director Vickers Venture Partners |
 |
||
| Thea Pham, PhD Associate, Investments OCV Partners |
Wednesday, March 23, 4 PM EDT
Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey
 |
 |
 |
| Greg Mannix VP of International Business Development Life Science Nation (Moderator) |
Russell McAllister, MBA CEO Bold Therapeutics |
Brian Hess, MBA CEO RevBio |
 |
||
| Alan Lucas Co-Founder, CEO & Director Navigation Sciences |
Thursday, March 24, 11 AM EDT
Precision Medicine
Improving Outcomes through a Patient-Tailored Approach
 |
 |
 |
| David Crean President & CEO Coast BioVentures |
Niall Kerrigan Program Manager Plug and Play Ventures |
Eric de la Fortelle Managing Partner Cathay Capital |
Thursday, March 24, 1 PM EDT
Cell & Gene Therapy
The Next Generation of Therapeutic Technologies
 |
 |
 |
| Nishta Rao Managing Director – Life Science First Republic Bank (Moderator) |
Cynthia Lavoie President & Chief Investment Officer Centre for Commercialization of Regenerative Medicine |
Scott Galasinski Global Head, Business Development, Licensing & Strategy, Biopharmaceuticals R&D AstraZeneca |
 |
 |
 |
| Megan Krench Director, Investments Sanofi Ventures |
Yury Kukushkin Investment Director JDRF T1D Fund |
Alicia Yin, PhD Vice President 6 Dimensions Capital |
Thursday, March 24, 2 PM EDT
Defining AI Investment
AI-Exclusive Investors Share Their Perspectives
 |
 |
 |
| Amit Garg, MBA Co-Founder & Managing Partner Tau Ventures (Moderator) |
Navid Alipour, JD, MBA Managing Partner Analytics Ventures |
Isabel Fox General Partner Outsized Ventures |
 |
||
| Gayathri Radhakrishnan, MBA Senior Director, Venture Capital – AI Fund Micron Technology |
Thursday, March 24, 4 PM EDT
Tales from the Road: Age-Tech Innovators on their Fundraising Journey
 |
 |
 |
| Jackie Marshall-Cyrus Director Jackie Marshall-Cyrus & Associates Ltd (Moderator) |
Char Hu, PhD Co-Founder & CEO The Helper Bees |
Meredith Oppenheim Founder & CEO Vitality Society |
 |
||
| Kyle Rand Co-Founder & CEO Rendever |
Digital RESI March Sponsors
17 MarBy Antoinette Lowre, Manager of Business Development, LSN
Digital RESI March starts next week, but the team knows that we cannot host five RESI events each year with the support, dedication, and enthusiasm of our sponsors! With their insight and involvement, RESI continues to bring panels, workshops, and the Innovator’s Pitch Challenge to the early-stage startup community to help them fundraise and grow successfully. Get to know the Digital RESI March sponsors and check out their workshops taking place virtually next week!
| Title Sponsors | |
 |
 |
| Gold Sponsors | |
 |
 |
 |
 |
| Exhibitors | |||
|
|||
|
If you’re looking to get involved in the early-stage startup community and share your brand and mission with the RESI network, view our sponsorship brochure to learn more about sponsorship opportunities at Digital RESI in 2022!
Pitch to Investors at Digital RESI June
17 MarBy Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Last week, we announced Digital RESI March’s Innovator’s Pitch Challenge (IPC) finalists who will be virtually exhibiting their innovative technologies through a dedicated landing page that includes their key marketing collateral and a recorded pitch video. These companies are also assigned to a live Q&A session featuring active investors and industry experts. The investors will ask high-level questions to the participating companies and provide helpful feedback. Not only does this help prepare companies for future investor meetings, but it has also even led to productive follow-up discussions between participating investors and finalists.
We are excited to continue the IPC for our next conference, Digital RESI, June 7-9. We are now taking applications – apply now to take advantage of this unique opportunity to showcase your innovative technology! Accepted finalists can also take advantage of super early bird registration rates and save $300 by April 15!
Digital RESI March will feature this excellent line-up of investor judges:
 Richard Anders Managing Director Mass Medical Angels |
 Yael Benvenisti CEO Mediterranean Tower Ventures |
 Chris Church Manager, Search & Evaluation, CVRM AstraZeneca |
 Adrien Clavairoly Senior Associate AdBio Partners |
 David Crean President & CEO Coast BioVentures |
 Adam Dakin Managing Director DreamIt Health |
 Abhinav Dey Manager, Business Development GreenFire Bio, LLC |
 Jacques Farges Investor Keiretsu Forum |
 Sarah Farr Associate Genesys Capital |
 David Fogel Angel Investor TiE Angels |
 Gary Gershony Partner BayMed Venture Partners |
 Tom Gibbs Director Debiopharm Innovation Fund |
 David Gordon Head of Investments Longliv Ventures |
 Jacob Grainger Ventures Associate & Program Manager Plug and Play Ventures |
 Brian Hakim Director of International Business Development MedtecX |
 Lu Han Partner Lumira Ventures |
 Amrita Jain Investment Professional LongeVC |
 Ray Jang Associate Primetime Partners |
 Quentin Langlois Vice President H.I.G. BioHealth Partners |
 Seo Lee Principal SV Investment |
 Matt Martin Venture Partner Pathway Bioventures |
 Petra Meyer Managing Director – HealthCare Sector Group Lead Golden Seeds |
 Jeffrey Moore President MP Healthcare Venture Management (MPH) |
 Liliana Nordbakk Chair Band of Angels |
 Nishta Rao Managing Director – Life Science First Republic Bank |
 Diana Saraceni Founder, Managing Director Panakes Partners |
 Bryan Shao K4 Deal Screening Committee Keiretsu Forum |
 Paras Sharma Associate Genesys Capital |
 Bill Trainor Co-Founder and Managing Director Mutual Capital Partners |
 Bill Tsai Investment Analyst, Bio Fund Taiwania Capital |
 Robert Tucci Member Director Texas Halo Fund |
 Sa’ar Yaniv Director of Business Development Fortress Biotech |
 Anthony Zlaket Venture Associate UnityPoint Health Ventures |
Hot Investor Mandate: Investment Platform with Billions of AUM Invests $10-15M in Advanced Therapeutics, Next-Generation Devices, Diagnostics, Tools, and More
17 MarAn investment platform with around €4B in assets under management spans both venture and private equity. Since its inception, the firm has completed 200+ investments. The firm’s latest fund, a dedicated healthcare and life science fund, targets venture and growth stage Tech-Enabled Medicine companies operating at the convergence of health, life sciences and technology. Investment sizes can range from $5M (Seed to Series A) to $50M (Crossover), with average initial check sizes expected to be around $10-15M, and a significant portion will be reserved for later rounds. The firm’s sweet spot is in Series B to C companies.
The firm invests globally across Asia, North America, and Europe (including Middle East). The firm is particularly interested in companies that want to expand to other geographic markets and assist companies to scale globally.
The firm will invest in six areas at the convergence of health, life sciences and technology:
- Life science tools – tools enabling advanced diagnostics / treatment: automated cell manufacturing & supply chain management for cell therapy, single cell manipulation, multi-omics consumables & reagents
- Diagnostics – enable more precise diagnostics, early detection, treatment support: clinical multi-omics, companion Dx, digital imaging / pathology with AI, clinical decision support systems
- Clinical trial enablement – finding the right patient and supporting distributed trials: patient subpopulation selection, trial site matching, virtual / decentralized trials, continuous trial monitoring, real world evidence
- Advanced Therapeutics – new modalities enabled by new technology: AI-driven drug discovery, cell & gene therapy, gene editing, microbiome, protein modulation, etc.
- New care models – changing point of care & virtual treatments: telehealth, digital therapeutics, digital mental health, wearables, chronic disease monitoring solutions
- Next-gen devices / materials – implantables enabled by novel materials / miniaturization, connected devices: biopolymers, non-invasive treatments, monitoring, closed loop therapies, robotic surgery, 3D printing
The firm likes to see strong management teams with proven track record and problem-solving skills or outstanding scientific founders.
The company should have innovation with impact, a clear development and regulatory approval pathway, and capital efficiency (defined timeline and budget and prudent approach to valuation). The firm can lead and co-invest depending on the investment opportunity, and seeks board representation when acting as the lead investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 